

## This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
<b>Cancer</b>				
Cancer	Breast cancer I early onset (BRCA1); BRCA2; cyclin dependent kinase 1 (CDK1; CDC2); poly(ADP-ribose) polymerase (PARP)	<p>Mouse studies suggest inhibiting CDK1 could help sensitize wild-type BRCA cancers to PARP inhibitors. In a mouse xenograft model of lung cancer with wild-type BRCA, combining small hairpin RNA-mediated CDK1 knockdown with PARP inhibition delayed tumor growth and increased survival compared with PARP inhibition alone. Next steps could include testing combinations of CDK1 and PARP inhibitors in additional animal models of cancer.</p> <p>Dinaciclib, a CDK inhibitor from Merck &amp; Co. Inc. and Ligand Pharmaceuticals Inc., is in Phase II testing for various cancers.</p> <p>Iniparib (BSI-201), a PARP inhibitor from Sanofi, is in Phase III testing to treat non-small cell lung cancer (NSCLC) and breast cancer, Phase II testing to treat ovarian cancer and Phase I testing to treat other cancers.</p> <p>At least eight other companies have PARP inhibitors in Phase II or earlier to treat various cancers.</p> <p><b>SciBX 4(27); doi:10.1038/scibx.2011.760</b>  <b>Published online July 14, 2011</b></p>	Patent and licensing status unavailable	<p>Johnson, N. <i>et al. Nat. Med.</i>; published online June 26, 2011; doi:10.1038/nm.2377</p> <p><b>Contact:</b> Geoffrey I. Shapiro, Dana-Farber Cancer Institute, Boston, Mass.  e-mail:  <a href="mailto:geoffrey_shapiro@dfci.harvard.edu">geoffrey_shapiro@dfci.harvard.edu</a></p>